Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Site Search
White will be the first person living with CF to lead the Board into a new era of CF
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs
Nonprofit commits $20 million to fund projects and accelerate genetic therapies for CF
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
Today, the Cystic Fibrosis Foundation awarded $2.76 million for 11 laboratory studies that will advance our understanding of the underlying factors that impact COVID-19 outcomes in people with cystic fibrosis. Ultimately, insights gained from this body of research may be used to improve future treatments.